{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:47:04Z","timestamp":1791424024928,"version":"4.3.3"},"reference-count":37,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T00:00:00Z","timestamp":1428364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The efficacy of treatment for hepatitis C genotype 1 infection has significantly improved with the introduction of first\u2010generation protease inhibitors. However, there remains a need for effective treatments for patients infected with other genotypes, for nonresponders and patients unsuitable for interferon. Sofosbuvir is the first nucleotide polymerase inhibitor with pan\u2010genotypic activity. Sofosbuvir\u2010based regimens have resulted in &gt;90% sustained virological response across treatment\u2010na\u00efve genotype 1\u20136 patients in five phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content> clinical trials of sofosbuvir administered with ribavirin or pegylated interferon and ribavirin. This analysis evaluates the cost\u2010effectiveness of sofosbuvir within the current licensed indication, for genotype 1\u20136 in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>. A Markov model followed a cohort of 10\u00a0000 patients over lifetime, with approximately 20% initiating treatment for compensated cirrhosis. Sofosbuvir\u2010regimens were compared to telaprevir, boceprevir, pegylated interferon and ribavirin, or no treatment. Costs and outcomes were discounted at 3.5%. The cost perspective utilized costs applicable to the National Health Service in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>. Sofosbuvir proved to be cost\u2010effective in most patient populations with incremental cost\u2010effectiveness ratios (<jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content>s) at \u00a311\u00a0836\/<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content> and \u00a37292\/<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content> against telaprevir and boceprevir, respectively. In genotype 3, sofosbuvir had a weighted <jats:styled-content style=\"fixed-case\">ICER<\/jats:styled-content> of \u00a318\u00a0761\/<jats:styled-content style=\"fixed-case\">QALY<\/jats:styled-content>. Sofosbuvir\u2010based regimens are a cost\u2010effective option for the majority of hepatitis C\u2010infected patients in the United Kingdom although the incremental cost\u2010effectiveness varies by genotype and regimen. Sofosbuvir and ribavirin is an alternative regimen for patients unsuitable for interferon.<\/jats:p>","DOI":"10.1111\/jvh.12409","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T05:52:17Z","timestamp":1428385937000},"page":"882-889","source":"Crossref","is-referenced-by-count":22,"title":["Cost\u2010effectiveness of sofosbuvir for the treatment of chronic hepatitis <scp>C<\/scp>\u2010infected patients"],"prefix":"10.1111","volume":"22","author":[{"given":"S.","family":"Cure","sequence":"first","affiliation":[{"name":"Mapi Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Guerra","sequence":"additional","affiliation":[{"name":"Mapi Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dusheiko","sequence":"additional","affiliation":[{"name":"UCL Division of Liver and Digestive Health Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3.47"},{"key":"e_1_2_8_3_1","volume-title":"Hepatitis C in the UK","author":"Public Health England","year":"2013"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12132"},{"key":"e_1_2_8_5_1","unstructured":"National Institute for Health and Clinical Excellence.Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C: Guidance 75 and 106 2010."},{"key":"e_1_2_8_6_1","unstructured":"National Institute for Health and Clinical Excellence.Boceprevir for the treatment of genotype 1 chronic hepatitis C \u2013 NICE technology appraisal guidance 253 2012. Available at:http:\/\/www.nice.org.uk\/guidance\/ta253\/resources\/guidance-boceprevir-for-the-treatment-of-genotype1-chronic-hepatitisc-pdf(accessed 18 June 2012)."},{"key":"e_1_2_8_7_1","unstructured":"National Institute for Health and Clinical Excellence.Telaprevir for the treatment of genotype 1 chronic hepatitis C \u2013 NICE technology appraisal guidance 252 2012. Available at:https:\/\/www.nice.org.uk\/guidance\/ta252(accessed 18 June 2012)."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-136-4-200202190-00008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2012.11.002"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.006"},{"key":"e_1_2_8_11_1","unstructured":"EMA.Sovaldi summary of product characteristics (SmPC) 2014. Available at:www.ema.europa.eu(accessed 5 February 2014)."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta11110"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15170"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26304"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"key":"e_1_2_8_17_1","unstructured":"National Institute for Health and Clinical Excellence.Guide to the methods of technology appraisal.2013."},{"key":"e_1_2_8_18_1","unstructured":"McLauchlanJ.Query of 5000 anonymised patient records performed October 2013. HCV UK Research Database 2013. Available at:http:\/\/www.hcvresearchuk.org\/?page=main(accessed October 2013)."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.023"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462309090229"},{"key":"e_1_2_8_21_1","unstructured":"Office for National Statistics.Births and deaths in England and Wales 2011. Available at:http:\/\/www.ons.gov.uk\/ons\/rel\/vsob1\/birth-summary-tables--england-and-wales\/2011--final-\/sb-births-and-deaths-in-england-and-wales--2011--final-.html(accessed 18 June 2012)."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta10210"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.12.006"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00130-8"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X05284108"},{"key":"e_1_2_8_26_1","unstructured":"British National Formulary.2013. Available at:https:\/\/www.medicinescomplete.com\/(accessed 19 June 2014)."},{"key":"e_1_2_8_27_1","volume-title":"NHS Reference Costs 2012 to 2013","author":"Department of Health","year":"2013"},{"key":"e_1_2_8_28_1","volume-title":"Unit Costs of Health and Social Care 2012","author":"Personal Social Services Unit","year":"2012"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.10"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta16040"},{"key":"e_1_2_8_31_1","unstructured":"Gilead Sciences.Positron Interim Synoptic Clinical Study Report GS\u2010US\u2010334\u20100107 Foster City. 13 A.D. Jan 23."},{"key":"e_1_2_8_32_1","unstructured":"Gilead Sciences.Fusion Interim Synoptic Clinical Study Report GS\u2010US\u2010334\u20100108 Foster City.2013. Mar 11."},{"key":"e_1_2_8_33_1","unstructured":"Gilead Sciences.Neutrino Interim Synoptic Clinical Study Report GS\u2010US\u2010334\u20100110 Foster City.2013. Feb 27."},{"key":"e_1_2_8_34_1","unstructured":"Gilead Sciences.Fission Interim Synoptic Clinical Study Report P7977\u20101231 Foster City.2013. Feb 25"},{"key":"e_1_2_8_35_1","unstructured":"Gilead Sciences.Valence Interim Synoptic Clinical Study Report Foster City.2013. Aug 10."},{"key":"e_1_2_8_36_1","volume-title":"EASL Recommendations on Treatment of Hepatitis C","author":"EASL","year":"2014"},{"key":"e_1_2_8_37_1","unstructured":"Genotype distribution from the PHE genotype surveillance report 2008\u20132012 page 9. Available at:https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/337115\/HCV_in_the_UK_2014_24_July.pdf(accessed 1 January 2014)."},{"issue":"9","key":"e_1_2_8_38_1","first-page":"605","article-title":"Fibroscan (transient elastography) for the measurement of liver fibrosis","volume":"8","author":"Afdhal N","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.12409","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T15:46:14Z","timestamp":1696261574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,7]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/jvh.12409"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12409","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,7]]}}}